School of Nursing and Health Studies, Hong Kong Metropolitan University Hong Kong China.
School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong Hong Kong China.
J Am Heart Assoc. 2023 Dec 19;12(24):e030943. doi: 10.1161/JAHA.123.030943. Epub 2023 Dec 18.
Establishing the sex-specific efficacy of cardiovascular medications is pivotal to evidence-based clinical practice, potentially closing the gender gap in longevity. Trials large enough to establish sex differences are unavailable. This study evaluated sex-specific effects of commonly prescribed cardiovascular medications on lifespan.
In a two-sample Mendelian randomization study, established genetic variants mimicking effects of lipid-lowering drugs, antihypertensives, and diabetes drugs were applied to genetic associations with lifespan proxied by UK Biobank maternal (n=412 937) and paternal (n=415 311) attained age. Estimates were obtained using inverse variance weighting, with sensitivity analyses where possible. For lipid-lowering drugs, genetically mimicked PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors were associated with longer lifespan, particularly in men (2.39 years per SD low-density lipoprotein cholesterol reduction [95% CI, 0.42-4.36], for interaction=0.14). Genetically mimicked treatments targeting , , or possibly were associated with longer lifespan in both sexes. For antihypertensives, genetically mimicked β-blockers and calcium channel blockers were associated with longer lifespan, particularly in men ( for interaction=0.17 for β-blockers and 0.31 for calcium channel blockers). For diabetes drugs, genetically mimicked metformin was associated with longer lifespan in both sexes. No associations were found for genetically mimicked statins, ezetimibe, or angiotensin-converting enzyme inhibitors.
PCSK9 inhibitors, β-blockers, and calcium channel blockers may prolong lifespan in the general population, particularly men. Treatments targeting , , or and metformin may be relevant to both sexes. Whether other null findings are attributable to lack of efficacy requires investigation. Further investigation of repurposing should be conducted.
确定心血管药物的性别特异性疗效对于循证临床实践至关重要,这可能有助于缩小长寿方面的性别差距。目前尚无足够大的试验来确定性别差异。本研究评估了常用心血管药物对寿命的性别特异性影响。
在两样本孟德尔随机化研究中,应用降脂药、降压药和糖尿病药物的既定遗传变异来模拟对寿命的遗传关联,寿命由英国生物库的母亲(n=412937)和父亲(n=415311)获得年龄来代表。使用逆方差加权法进行估计,并尽可能进行敏感性分析。对于降脂药物,基因模拟的 PCSK9(前蛋白转化酶枯草溶菌素/糜蛋白酶 9)抑制剂与寿命延长相关,特别是在男性中(每降低 SD 低密度脂蛋白胆固醇 2.39 年[95%CI,0.42-4.36],交互作用=0.14)。针对 、 或可能针对 的基因模拟治疗与两性的寿命延长相关。对于降压药物,基因模拟的β受体阻滞剂和钙通道阻滞剂与寿命延长相关,特别是在男性中(β受体阻滞剂交互作用=0.17,钙通道阻滞剂交互作用=0.31)。对于糖尿病药物,基因模拟的二甲双胍与两性的寿命延长相关。基因模拟的他汀类药物、依折麦布或血管紧张素转换酶抑制剂与寿命延长无关。
PCSK9 抑制剂、β受体阻滞剂和钙通道阻滞剂可能使普通人群,尤其是男性的寿命延长。针对 、 或 以及二甲双胍的治疗可能对两性都有意义。其他阴性结果是否归因于缺乏疗效需要进一步调查。应进一步开展重新定位治疗的研究。